Cite
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
MLA
Bernd Gerber, et al. “Genetic Variants in VEGF Pathway Genes in Neoadjuvant Breast Cancer Patients Receiving Bevacizumab: Results from the Randomized Phase III GeparQuinto Study.” International Journal of Cancer, vol. 137, July 2015, pp. 2981–88. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........03c45e0b1c7b7da1405aaf3baf229392&authtype=sso&custid=ns315887.
APA
Bernd Gerber, Diether Lambrechts, Mahdi Rezai, Matthieu Moisse, Christian Schem, Jens Huober, Volkmar Müller, Georg Kunz, Claus Hanusch, Serban-Dan Costa, Gilian Peuteman, K. Schwedler, Richard M. Weinshilboum, Brigitte Rack, Jens Uwe Blohmer, Peter A. Fasching, Thomas Van Brussel, Valentina Nekljudova, K Kittel, … Tanja Fehm. (2015). Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. International Journal of Cancer, 137, 2981–2988.
Chicago
Bernd Gerber, Diether Lambrechts, Mahdi Rezai, Matthieu Moisse, Christian Schem, Jens Huober, Volkmar Müller, et al. 2015. “Genetic Variants in VEGF Pathway Genes in Neoadjuvant Breast Cancer Patients Receiving Bevacizumab: Results from the Randomized Phase III GeparQuinto Study.” International Journal of Cancer 137 (July): 2981–88. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........03c45e0b1c7b7da1405aaf3baf229392&authtype=sso&custid=ns315887.